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SUMMARY 21 
Group 2 innate lymphoid cells (ILC2s) play crucial roles in type 2 immune responses 22 
associated with allergic and autoimmune diseases, viral and helminth infections and tissue 23 
homeostasis. Experimental models show that in helminth infections ILC2s provide an early 24 
source of type 2 cytokines and therefore are essential for the induction of potentially 25 
protective type 2 responses. Much of our knowledge of ILC2s in helminth infections has 26 
come from experimental mouse models with very few studies analysing ILC2s in natural 27 
human infections. 28 
In attempts to harness knowledge from paradigms of the development of protective 29 
immunity in human helminth infections for vaccine development, the role of ILC2 cells could 30 
be pivotal. So far, potential vaccines against human helminth infections have failed to 31 
provide effective protection when evaluated in human studies. In addition to appropriate 32 
antigen selection, it is apparent that more detailed knowledge on mechanisms of induction 33 
and maintenance of protective immune responses is required. Therefore, there is need to 34 
understand how ILC2 cells induce type 2 responses and subsequently support the 35 
development of a protective immune response in the context of immunizations. Within this 36 
review, we summarize the current knowledge of the biology of ILC2s, discuss the importance 37 
of ILC2s in human helminth infections and explore how ILC2 responses could be boosted to 38 
efficiently induce protective immunity.     39 
 3 
INTRODUCTION: 40 
 41 
Group 2 Innate lymphoid cells (ILC2s) were originally identified in experimental mouse 42 
models of helminth infections. Several studies published in 2010 utilized reporter mouse 43 
strains marking either interleukin (IL-)13 [1] or IL-4 [2] producing cells to identify a cell type, 44 
which did not express classical lineage markers of T, B, NK, myeloid or dendritic cells [2]. 45 
These lineage-negative innate lymphocytes produced classical T helper-type 2 (TH2) 46 
cytokines in response to IL-25 and IL-33. In mice infected with the murine helminth parasite 47 
Nippostrongylus brasiliensis, these cells acted as an early source of IL-13 and were essential 48 
for timely worm expulsion [1, 2]. These innate cells, later designated as ILC2s [3], are now 49 
well characterised and their importance in mediating pathology in asthmatic and allergic 50 
diseases as well as in viral infections has been described (reviewed in [4-7]). Subsequently 51 
further innate lymphoid cells were described mirroring the different adaptive CD4+ T cells; 52 
group 1 Innate lymphoid cells (ILC1s) are the innate counterparts of TH1 CD4+ T cells, ILC2s 53 
are the counterpart of TH2 CD4+ T cells and group 3 innate lymphoid cells (ILC3s) mirror TH17 54 
and TH22 (reviewed in [8]). In contrast to T helper CD4+ T cells, and despite the fact that they 55 
are of lymphoid origin, ILCs do not express T cell receptors and lack any antigen specificity. 56 
The discovery of innate lymphoid cells has introduced a new immunological field and 57 
transformed our understanding of innate immune responses and the generation of the 58 
adaptive immune system.  59 
 60 
Experimental studies have demonstrated that ILC2 cells are involved in tissue repair and 61 
homeostasis [9] (reviewed in [10]) which is an important consideration for tissue dwelling 62 
helminth. In addition, the involvement in parasite expulsion in intestinal helminths makes 63 
these cells important in immune protection against helminth infection and pathology. In one 64 
of only two studies of ILC2s in natural human helminth infection, we have shown that ILC2 65 
cells are diminished in schistosome infected children and are restored to levels observed in 66 
children who are exposed to infection but remain uninfected following curative 67 
antihelminthic treatment [11].   68 
Within this review, we will discuss the current knowledge of the biology, function and 69 
regulation of ILC2s, their ‘potential’ importance in human helminth infections and 70 
possibilities of utilizing ILC2 to boost protective immune response induced following 71 
treatment and vaccination. This knowledge could inform helminth control efforts as calls for 72 
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helminth vaccine development escalate in light of global mandates such as ‘Sustainable 73 
Development Goal 3’ advocating for eradication or elimination of helminth infection.  74 
 5 
THE BIOLOGY OF GROUP 2 INNATE LYMPHOID CELLS 75 
In mice, ILC2s were originally identified as a type 2 cytokine expressing cell subset, which 76 
could not be classified by conventional lineage markers for T cells, B cells, NK cells, 77 
macrophages, dendritic cells, neutrophils, eosinohphils, basophils or mast cells, but 78 
expressed the common leucocyte antigen (LCA) CD45 and their morphology resembled 79 
those of typical lymphocytes [1, 2, 12]. Early studies identified the markers IL-17 receptor B, 80 
in combination with IL-17RA forming the IL-25 receptor, the IL-33 receptor (T1/ST2) with 81 
varying expression of the stem cell factor c-kit (CD117) [1, 2]. These innate lymphoid- like 82 
cells, were given various names including nuocytes [1], innate helper type 2 cells (Ih2) [2] or 83 
natural helper cells [13]. They were enriched in mesentery [13] and have been shown to   84 
express the common gamma chain (γc, CD132) associated receptors CD25 (IL-2R) and 85 
CD127 (IL-7R). IL-7 be has been shown to play an essential role in the development and 86 
survival of ILC2s and ILC3s [14-16].     87 
 88 
Human ILC2s were initially described by Mjosberg et al. [17] as being similar to murine ILC2s 89 
in lacking the expression of classical lineage defining markers, but being positive for the 90 
leucocyte marker CD45 and the IL-7R (CD127). In addition, human ILC2s express the 91 
‘chemokine receptor homologous molecule expressed on TH2 cells’ (CRTH2 = CD294) [17], a 92 
marker well characterised for its expression on human CD4+ TH2 cells [18], the NK cell 93 
receptor NKR-P1A (CD161) [17] and ST2 [19] (a member of the IL-1 family receptors), which 94 
is part of the IL-33 receptor complex [20]. A combination of these markers is frequently used 95 
for identifying human ILC2s as Lin-CD45+CD127+CRTH2+CD161+(ST2+) [11, 17, 21-23] as we 96 
depict in the flow chart for analysing human ILC2 by flow cytometry (Figure 1).  97 
 98 
Apart from the IL-7R, ILC2s express the IL-2R (CD25) [17] and both IL-2 and IL-7 are 99 
indispensable for the development, homeostasis and activation of ILC2s [13, 24, 25]. The IL-100 
7R chain forms a heterodimer with the ‘thymic stromal lymphopoietin’ (TSLP) receptor [26] 101 
a further characteristic marker of human ILC2s [25]. TSLP is able to activate cytokine 102 
production by ILC2s, but works more efficiently in combination with IL-2 and has synergistic 103 
effects with IL-33 [25]. IL-33 (or IL-1F11) is a IL-1 family member and acts via the IL-33 104 
receptor [20]. Furthermore IL-25 activates cytokines production by ILC2s signalling via the IL-105 
25 receptor, a heterodimer of IL-17RB and IL-17RA. IL-25, IL-33 and TSLP can be seen as the 106 
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classical ILC2 activating cytokines and often referred to as alarmins (alarm signals). 107 
Hematopoietic cells can produce alarmins, but the primary sources are non-hematopoietic 108 
cells. IL-33 is primary produced by endothelial and epithelial cells [27-29], but can be 109 
released by macrophages [30] or dendritic cells [31]. In contrast, tuft cells, a subset of 110 
epithelial cells of the small intestine with previously more or less unknown function, were 111 
identified as a major source of IL-25 [32-34], which is required for ILC2 homeostasis. The 112 
numbers of tuft cells increase significantly when exposed to intestinal parasites. 113 
 114 
ILC2s express a variety of additional receptors involved in the activation and homeostasis. 115 
Expression of the IL-4R (CD124) was shown in mice and basophil derived IL-4 can positively 116 
control ILC2s [35]. Since IL-4 is secreted by ILC2s, IL-4 could potentially act as an autocrine 117 
feedback mechanism for activation of ILC2s. However, the exact role of IL-4 in controlling 118 
activation of human ILC2s is currently unknown. ILC2s are also the main source of IL-9, 119 
another common γ chain (γc) cytokine, [36, 37], with expression of IL-9 receptor being 120 
essential for ILC2 activation, survival of activated ILC2s and finally for efficient helminth 121 
worm expulsion in mouse experimental models [36]. IL-9 released by lung resident ILC2s 122 
plays a central role in the epithelial response to murine N. brasiliensis infection by inducing 123 
IL-5 and IL-13 production [38]. Gene expression analyses indicated that the IL-9 receptor is 124 
expressed on murine ILC2s, and in humans, expression of this receptor has been shown on 125 
blood and lung ILC2s [21]. The CRTH2 is a crucial marker for the identification of human 126 
ILC2s [17] and for classical TH2 cells [18, 39]. The agonist for CRTH2 is prostaglandin (PG)D2, 127 
a well characterised mediator of allergic asthma [40] released by activated mast cells. PGD2 128 
is crucial for chemotaxis of TH2 cells [41] and drives accumulation of ILC2s in inflamed tissues 129 
[42].     130 
 131 
Murine ILC2s isolated from lymphnodes and the spleen, and to a less extent, ILC2s from the 132 
peritoneal or broncho-alveolar lavage, express major histocompatibility complex class-II 133 
(MHC-II) molecules. They also express the co-stimulatory molecules CD80 and CD86 [43]. 134 
Expression of MHC-II in combination with co-stimulatory molecules allows a direct 135 
interaction with CD4+ T cells and can drive CD4+ T cell expansion and activation and TH2 136 
polarisation and is important for efficient worm expulsion in murine infections of N. 137 
brasiliensis. Accordingly, it had been demonstrated that human ILC2s isolated from 138 
 7 
peripheral blood express high levels of HLR-DR, CD80 and CD86 [43].  139 
 140 
Similar to all other immune responses, the function of ILC2s needs counter-regulation 141 
allowing control of their function. Type 1 and type 2 interferons can negatively regulate 142 
ILC2s [23, 44] and both types of interferons are long known to inhibit helminth driven TH2 143 
responses. Additionally ILC2s can be suppressed by IL-27 [45] and express the inhibitory 144 
receptor killer-cell lectin like receptor G1 (KLRG1). In human ILC2s, the ligand of KLRG1, E-145 
cadherin, inhibited expression of GATA3 and production of TH2-cytokines [46]. GATA3, the 146 
transcription factor essential for TH2 CD4+ T cell polarization and function, is crucial for ILC2 147 
differentiation, maintenance and activation [24, 25], and also used as identifying marker to 148 
distinguish them from other ILC subsets. Furthermore, development, differentiation and 149 
function of ILC2s depend on ROR [16, 47], T cell factor-1 (TCF-1) [48] and GFI1 [49]. 150 
 151 
ILC2s are now considered to play a central role in inducing type 2 immune responses in mice. 152 
Following activation, ILC2s secrete type-2 cytokines and activate various and complex 153 
immune responses, which are characteristic for type 2 responses including B cell activation 154 
and isotype switching to IgE, induction of eosinophilia, polarisation of alternative activated 155 
macrophages and initiation of an adaptive TH2 T cell response including generation of TH2 156 
memory CD4+ T cells as outlined and described in Figure 2.  157 
 158 
Common γc – cytokine receptors  159 
Common gamma chain (γc) (CD132) cytokine receptors play a central role in the 160 
development, homoeostasis and function of several immune cell lineages and are 161 
indispensable for the immune system itself. Therefore, it is not surprising that common γc-162 
cytokines and the corresponding receptors are also essential for the development of ILC2s. 163 
The IL-7Rα chain, forming a heterodimer with the common γc (also known as common IL-2 164 
receptor gamma chain), was one of the first surface receptors identified as marker for ILCs 165 
and the development of ILC2s was depending on the common γc and IL-7 [13]. The IL-2Rα is 166 
also a marker human ILC2s and provides an important co-stimulatory signal for the 167 
activation of ILC2s [25].  168 
 169 
Using a reporter mouse strain, ILC2s, rather than CD4+ T cells, were also identified as main 170 
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source of IL-9 in a model of airway inflammation [37]. More importantly IL-9 acts as 171 
feedback signal enhancing the cytokine production by ILC2s. The importance of IL-9 as a 172 
feedback signal was subsequently confirmed in experimental infection with N. brasiliensis, in 173 
which IL-9 receptor expressing ILC2 are important for restoring tissue damage caused by the 174 
lung stage of N. brasiliensis [36, 38]. Hence common γc receptors play a pivotal in the 175 
development, maintenance and activation of ILC2s. 176 
 177 
 In T cells, common γc – signalling is mainly mediated by three pathways: the JAK-STAT 178 
pathway, the Mitogen-activated protein kinases (MAPK)-Erk pathway and the 179 
Phosphoinositide 3-kinase (PI3K)-pathway. Binding of cytokines to its corresponding 180 
receptors leads to an activation of Janus Kinases (JAK) which are associated to the receptor 181 
(reviewed in [50]). JAK activation leads to a phosphorylation of tyrosine residues within the 182 
receptor chain causing binding, phosphorylation and dimerization of signal transducer and 183 
activator of transcription (STAT), which then translocate to the nucleus and starts specific 184 
transcription. There are several STAT molecules partially determining specific effects of 185 
cytokines. IL-2, IL-7 and IL-9 mainly activate STAT5, whereas IL-4 mainly induces the 186 
activation of STAT6. Interestingly the TSLPR, which contains a IL-7Rα chain, but no common 187 
γc, activates STAT5 in a JAK independent way [51]. IL-2 and TSLP efficiently induce STAT5 188 
phosphorylation in human ILC2s, while IL-33 elicits a moderate phosphorylation of STAT3 189 
[25]. 190 
 191 
The JAK-STAT signalling pathway is tightly regulated to control strength, duration and 192 
specificity of activation. Suppressor of cytokine signalling (SOCS) molecule comprise a family 193 
of eight members SOCS1-SOCS7 and the cytokine-inducible SH2 domain protein (CISH) of 194 
which four are shown to be important in T cell signalling (CISH, SOCS1-SOCS3) (reviewed in 195 
[52]). The SOCS molecules including CISH have been shown to regulate STAT signalling and 196 
modulate T helper polarisation [53-55]. Both the MAPK-Erk as well as the PI3K pathways play 197 
central roles in the development, homeostasis and functions of several innate and adaptive 198 
immune cells. Both pathways contribute to T helper polarisation [56-59] including 199 
differentiation of TH2 cells [60, 61]. While the importance of common γc cytokine receptors 200 
for ILC2s is well described for mice, the precise signalling pathways controlling the 201 
development and function of human ILC2s remain to be investigated.  202 
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 203 
LOCATION OF ILC2s AND THE IMPLICATION FOR HUMAN HELMINTH INFECTIONS 204 
ILC2s have been identified in various tissues. Using reporter mice in experimental models of 205 
N. brasiliensis infection, ILC2s were identified in the spleen, liver, mesenteric lymphnodes,  206 
the intestine, fat-associated lymphoid clusters [1, 2, 13] and in skin [62]. In humans, ILC2s 207 
have been described in nasal polyps, tonsils, gastrointestinal tract, peripheral blood [17, 25] 208 
and the lung [9, 17]. ILC2 are also described in human skin [46, 63] with their migration to 209 
the skin being associated with PGD2, the ligand for CRTH2 [63], and the skin-homing marker 210 
cutaneous lymphocyte antigen [64]. Overall, mucosa-associated tissue of the lung, intestine 211 
and skin are now widely accepted as the most important locations for ILC2s.  212 
 213 
Helminths have complicated and diverse life histories, differing in their route and site of 214 
infection, migration within the human host, location of adult worms and exit of juveniles or 215 
eggs. This diversity in helminth biology results in heterogeneous acquired immune responses 216 
to helminth parasites reflected by fundamental differences in in vitro experiments and in 217 
immuno-epidemiological studies (reviewed in [65]). These life history differences together 218 
with differences in niches relative to the location of ILC2s, imply differences in the encounter 219 
between the parasite/parasite products and ILC2 cells. For instance, helminths such as 220 
Schistosoma spp. (a trematode), Strongyloides stercoralis or hookworms (Ancylostoma 221 
duodenale and Necator americanus; nematodes) are skin-penetrating parasites, meaning 222 
that the infective stage and/or the tissue damage caused by the skin-penetration, can trigger 223 
ILC2s.  224 
A percutaneous infection by Schistosoma mansoni larvae elicits a transient expression of 225 
TSLP and IL-33 [66]. Although not directly shown, the release of the cytokines is likely to 226 
activate ILC2s. Larvae (L3) of vector-transmitted filarial nematodes (Wucheria bancrofti, 227 
Brugia malayi, Loa Loa, Mansonella perstans) also need to penetrate the skin or the bite 228 
wound during the blood meal of the vector. Onchocerca volvulus, Mansonella streptocerca 229 
and Loa Loa directly develop a cutaneous filariasis with adults residing in subcutaneous 230 
tissues. It remains to be investigated whether dermal ILC2s do indeed play a role in initiating 231 
anti-filarial immune responses following skin penetration and in cutaneous filariasis.   232 
Infection via the skin causes a certain degree of tissue damage [67] and induces wound 233 
healing [66]. ILC2s are crucial for cutaneous wound healing [68]. These data suggest that, it 234 
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ILC2s may have an additional function in wound healing of damaged tissue caused by skin-235 
penetrating parasites. 236 
 237 
Several helminth species have evolved a critical lung stage, which can be either transient 238 
(Ascaris, Schistosoma, Strongyloides spp.) or more persistent (W. bancrofti, B. malayi, Loa 239 
Loa) (reviewed in [69]). Lung stages of helminths can cause tissue damage in the lung and 240 
affect mucosal integrity. In experimental mouse models, the crucial role of ILC2, mediated by 241 
IL-9, acting in autocrine manner, in tissue repair and lung homeostasis has been well-242 
documented [36-38]. Activated macrophages are also involved in limiting tissue damage 243 
during lung migration, a process requiring IL-4/IL-13 signalling [70], although in this former 244 
study the exact source of these cytokines was not determined, ILC2s should be considered as 245 
source of these cytokines. Mature adults of gastrointestinal helminths (hookworms, S. 246 
stercoralis) reside in different parts of the intestine and influence and/or damage the 247 
epithelial tissue resulting in a release of IL-25, IL-33 and TSLP, triggering ILC2s [71]. Since the 248 
intestinal tissue is a main compartment where ILC2s are located, it is likely that activated 249 
ILC2s play a major role in initiating the immune response in these helminth infections. It will 250 
be difficult to prove this role of intestinal ILC2s in a human infection, but mouse 251 
experimental studies strongly support this as reviewed in [72]. 252 
Adult schistosomes reside in mesenteric (S. mansoni, S. japonicum) or in perivesicular 253 
venules (S. haematobium) [73] were they interact with the epithelium. Moreover eggs 254 
released by the females need to penetrate the bladder wall (S. haematobium) or migrate to 255 
the intestine (S. mansoni), damaging epithelial tissue. As outlined above damaging the 256 
epithelium could trigger ILC2s, but so far there are no studies investigating whether 257 
schistosomes induce ILC2 directly or indirectly through tissue damage.  258 
 259 
ILCs derive from a common lymphoid precursor in bone marrow [74] expressing the integrin 260 
α4β7, mediating migration to endothelial venues and mucosal tissues, and chemokine 261 
receptor CXCR6 mediating migration to the intestine [75]. Additionally, a lineage-specific 262 
precursor has been identified for ILC2s [24, 47]. However, it has been suggested that ILC2s 263 
proliferate within tissues and are rarely replenished from the bone marrow [45]. More 264 
committed progenitors were also identified in secondary lymphoid organs [76]. Therefore 265 
the contribution of circulating ILC2s from peripheral blood to tissue-resident ILC2 pool needs 266 
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to be studied in more detail to allow interpretation of immuno-epidemiological data based 267 
on human blood, as theoretically, blood ILC2s maybe important in blood residing pathogens 268 
including schistosomes. 269 
 270 
Much of our knowledge about ILC2s in helminth infections derives from experimental 271 
infection with N. brasiliensis, a murine gastrointestinal parasite and most experimental 272 
infections cover days or a few weeks following initial infection. In human, however, adult 273 
worms can live for years, and in the case of Schistosoma spp. even decades [77]. For people 274 
living in endemic areas, an infection does not occur solely at a single time point, but instead 275 
occurs more gradually with multiple infection events, resulting in hosts carrying different life 276 
stages of the parasites concurrently. Hence, most helminth parasite can cause a chronic 277 
long-lasting disease, which cannot be recapitulated in the mouse experimental model. 278 
Hence, knowledge about the function and importance of ILC2 obtained from experimental 279 
models cannot necessarily extrapolated to natural human infections.  280 
 281 
ILC2s IN HUMAN HELMINTH INFECTION – WHAT WE DO ‘NOT’ KNOW.  282 
So far there are very few studies that have analysed ILC2s in natural human helminth 283 
infection, a fact, which is not surprising considering the history and biology of ILC2s outlined 284 
above. ILC2s constitute a small fraction of human blood leucocytes. In our studies in a 285 
Zimbabwean population a mean of 0.031% (median 0.023%, rage 0.003-0.133, N=72) of live-286 
gated leucocytes was denoted as ILC2s, a proportion which is comparable to data published 287 
elsewhere [17] and data in Caucasians (unpublished data). Of note, ILC2s are hardly 288 
detectable in peripheral blood of naïve mice [1, 2].  289 
In humans, proportions are slightly higher in the skin, ileum, lung and tonsils compared to 290 
peripheral blood and are increased in inflamed tissues such as inflamed nasal polyps and 291 
skin lesions of patients with atopic dermatitis [17, 46, 64, 78]. Furthermore, proportions of 292 
ILC2s are increased in lung specimens of patients with severe forms of asthma. However, it 293 
remains contradictory whether the proportions of ILC2s are higher in lung specimens 294 
compared to blood of the same patient [79, 80]. Such analyses of human tissues are 295 
informative but are beyond the scope of immuno-epidemiological approaches such as the 296 
ones we have previously published.  297 
 298 
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Nevertheless, there have been some advances in studying human ILC2 cells in the context of 299 
natural human infections. Nutman and colleagues analysed ILCs defined as lin-300 
CD45+CD127+CD117+ (c-kit), comprising both ILC2s and ILC3s, in peripheral blood of filarial 301 
infected adults (Loa Loa, W. bancrofti, O. volvulus) [81]. The frequency of c-kit+ ILCs and IL-302 
13 producing cells among c-kit+ ILCs were increased in filarial infected individuals. The 303 
proportion of c-kit ILCs correlated with IL-17 producing CD4+ T cells and ex vivo stimulation 304 
of enriched ILCs released IL-5 and IL-13, but also IL-10, IL-17 and IFNγ [81].  305 
In a different study, we evaluated ILC2s in context of natural infection with S. haemtobium in 306 
Zimbabwean children [11]. Schistosome-infected children aged 6-13 years (as diagnosed by 307 
parasite egg excretion) had a significantly lower frequency of ILC2s in the peripheral blood 308 
compared to same age schistosome uninfected children (Figure 3A). In contrast, older 309 
infected children (aged 14-18 years) had comparable levels of ILC2s to uninfected children 310 
[11]. Proportions of ILC2s recovered following curative anti-helminthic treatment (Figure 311 
3B). Of note is the difference in these age groups; children are exposed to schistosome 312 
infection very young and therefore acquire infection at a young age [82]. By the time they 313 
reach adolescence, they will have experienced several re-infection events. Thus, it is possible 314 
that the ILC2 dynamics are reflecting differences occurring upon first versus repeated 315 
infection events. Older egg positive children had levels of ILC2s comparable to same age egg 316 
negative children. These older egg positive children show a schistosome-specific antibody 317 
profile, which indicates a history of previous infection and also associated with the 318 
development of protective immunity, beginning to reduce re-infection levels [83-85]. This 319 
finding may indicate that ILC2s play a more pronounced role in the initiation of early 320 
immune response at a stage when effective TH2 responses are triggered and a full CD4+ T 321 
cell mediated TH2 response has not yet developed. In this context it would be interesting to 322 
perform long-term follow-up studies, which analyse if early changes in the proportion or 323 
phenotype of ILC2 are predictive for the development of, or the nature of a protective 324 
immune response. The study analysing ILCs in filarial infections mentioned above [81] found 325 
increased proportions of ILCs in infected adults, which may indicate a complete contrasting 326 
function of ILCs in adults. For instance, ILC2s could play a role in diminishing tissue damage 327 
and promote epithelial healing to limit pathology or alternatively contribute to pathology. 328 
Differences between the two studies could reflect differences in the biology of trematodes 329 
and filarial nematodes. For instance, filarial parasites frequently harbour Wolbachia spp. 330 
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endosymbionts [86], which could trigger TLR responses and potentially modify the response 331 
elicited by various ILC subsets including ILC2s and ILC3s. Whereas the precise pattern of TLR 332 
expression on ILC2s has not yet been specified, LTi-like group 3 ILCs have been shown to 333 
express TLRs [87]. Of note, the study by Boyd et al analysed CD127+CD117+ ILCs comprising 334 
both ILC2s and ILC3s [81]. To analyse the contribution of Wolbachia endosymbionts to ILC 335 
mediated immune responses, interventional studies with doxycycline, which targets 336 
Wolbachia spp. in filarial infections could be utilized [88-90]. Furthermore, differences in the 337 
life cycle and age dynamics in different types of helminth infections could contribute to 338 
differences in ILC2s. Therefore, additional observational and interventional studies are 339 
required to decipher the precise role of ILC2s in various helminth infections and in the 340 
context of the complex dynamics of human helminth infections, which cannot completely be 341 
mimicked by experimental models. The mechanism responsible for differences in the 342 
frequency of ILC2 in peripheral blood in these human helminth studies remains unknown. 343 
One possibility is that one or all of proliferation, survival and homoeostasis of ILC2 is altered 344 
during helminth infection. Common γc cytokine signalling (as outlined above) could be 345 
altered during helminth infections. Chronic down-modulation of IL-7Rα on memory T cells 346 
has been shown for chronic viral infections [91, 92], a mechanism potentially affecting ILC2s 347 
in chronic parasite infections. However, expression of the IL-7Rα chain on the surface of ILC2 348 
was not altered during schistosome infections [11]. Regulation of IL-7 signalling is much 349 
more complex and could depend on the availability of IL-7 and levels of soluble IL-7Rα 350 
(generated by alternative splicing [93]), which has been shown to inhibit IL-7 uptake [94] or 351 
function as IL-7 reservoir [95]. Aberrant levels of plasma IL-7 and soluble IL-7R were recently 352 
shown in the context of human tuberculosis [96].  In addition, modulation of downstream 353 
signalling in particular of the JAK-STAT pathway including modulation of SOCS may influence 354 
homeostasis and responsiveness of human ILC2s. Modulation of this signalling pathway in T 355 
cells has been shown for various infectious diseases including tuberculosis [97]. Whether 356 
and to which degree common γc signalling is modulated in ILC2s in particular during 357 
helminth infection remains elusive. Furthermore, modulation of signalling via the IL-9R and 358 
TSLPR could be regulated and may provide molecular targets for chemoprophylaxis or 359 
therapy. 360 
 361 
The impact of nutrition, particularly micronutrients on the immune system is well 362 
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established in experimental models. Micronutrient deficiency is widespread in helminth 363 
endemic areas with Vitamin A deficiency being one of the most common. Interestingly, work 364 
in experimental studies indicates that Vitamin A deficiency is characterised by an increase in 365 
ILC2 cells and increased production of IL-13 by these cells to maintain mucosal barrier 366 
immunity to helminth infection under malnutrition [98]. In addition, recent work has also 367 
highlighted that ILC2 cells predominantly depend on fatty acid (FA) metabolism during 368 
helminth infection [99]. The vast majority of the world's malnourished people live in 369 
developing countries, where 13.5% of the population is undernourished [100] and areas of 370 
malnutrition largely overlap with helminth endemic areas. Therefore, it is important to 371 
understand the development and function of ILC2 cells in populations exposed to  helminth 372 
infection. There are many potential sources of heterogeneity, not least the gut microbiome 373 
structure. Mouse experimental studies have demonstrated that infection with the helminth 374 
Trichuris muris significantly altered the host gut microbiome structure, reducing the diversity 375 
and abundance of the Bacteroidetes, Prevotella and Parabacteroidetes [101]. This dysbiosis 376 
was associated with a significant reduction in amounts of Vitamin D derivatives and a 377 
reduction in the breakdown of dietary plant derived carbohydrates involved in amino acid 378 
synthesis, with an associated reduction in the weight of the infected animals. We have 379 
demonstrated that the gut microbiome structure in children infected with schistosomes 380 
differed significantly from that of uninfected children from the same community [102]. 381 
Although the development of ILC2 cells does not seem dependent on the gut microbiome, 382 
their function is dependent on the colonisation of the gut by commensals (reviewed in 383 
[103]). However, the precise mechanisms of how/which signals from the gut microbes 384 
interact with the ILC2 to facilitate their maturation and function remains unknown. Answers 385 
to these questions will only come from studies conducted in context, in the relavant human 386 
populations. 387 
 388 
To date both experimental and human studies have mainly focused on infection. However, 389 
there is also another aspect of human helminthiases in which the immune response plays a 390 
central role; i.e. immunopathology. Eggs are mainly responsible for the pathology associated 391 
schistosomiasis and egg-induced immunopathology can occour in the chronic form of the 392 
disease. Eggs laid by adults worms, which reside in the vesical plexus of the bladder or 393 
mesenteric veins of the liver, can be carried to portal venules in the liver and to the bladder 394 
 15 
or genital tract where eggs become trapped and eventually form granulomas and can induce 395 
immune-mediated fibrosis. The degree of pathology depends on the balance of type-1, type-396 
2 and type-17 immune responses (reviewed in [104, 105]). Servere forms of pathology are 397 
associated with TH1/TH17, wherease mild pathology is associated with a combination of 398 
regulatory and TH2 response. However, the type-2 cytokine IL-13 also contributes to hepatic 399 
fibrosis [106]. In mouse models, it has been shown that ILC2s are a likely source for IL-13 in 400 
hepatic fibrosis [107]. Hepatic IL-33 triggered the expansion and activation of liver resident 401 
ILC2s, which produced IL-13 and mediated fibrosis [107, 108]. In human intestinal 402 
schistosomiasis, the majority of patients develop a less severe form of the disease, but about 403 
5-10% suffer from hepatosplenic schistosomiasis with progressive fibrosis [109]. To what 404 
extend hepatic ILC2s contribute to the development of servere forms of schistosomiasis 405 
remains to be investigated. Furthermore, the impact of environmental enteropathy which 406 
affects gut permeability, execrebated by helminth infections has yet to be investigated 407 
[110].  408 
 409 
THE POTENTIAL IMPACT FOR TREATMENT STRATEGIES AND SUCCESSFUL VACCINATION 410 
The development of successful vaccinations against human parasitic infections and in 411 
particular against helminth infections has proven challenging. Although there are some 412 
promising vaccine candidates for instance, a vaccine against hookworms [111], currently 413 
there is no licenced vaccine against helminth infections for use in human. The reasons for 414 
lack of progress in human helminth vaccinology are manifold. Most helminths have complex 415 
life cycles with intermediates hosts and reservoirs and several life cycle stages even within 416 
the human host leading to highly variable and complex antigen pattern. Helminths typically 417 
induce a type 2 response, which is potentially protective. However, work over the last 418 
decade has shown that helminths have evolved immune evasion mechanisms allowing the 419 
establishment of long-lasting infections and modulation of pathology (reviewed in [112-420 
115]). To do so, helminths utilize immunosuppressive and immunoevasive mechanisms, 421 
mediated through various mechanisms. For instance, the importance of regulatory T cells 422 
has been shown for filarial [116, 117] and schistosome infections [118, 119] and excretory-423 
secretory products released by helminth parasites can directly induce regulatory T cells 424 
[120]. In the cases of schistosomiasis suppression of immune responses induced by worms 425 
can delay the development of protective immunity [121]. Mechanisms of how the host 426 
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eventually manage to express a resistance phenotype have been a subject of our research, 427 
leading to the description of the threshold hypothesis [122]; i.e. the host needs to 428 
experience a threshold of antigens to mount an effective immune response and that these 429 
antigens become available following worm death. We and others have also demonstrated 430 
the requirement of the ratio of regulatory vs. effector cellular immune to favour effector 431 
responses for expression of resistance [118]. However, the precise mechanism of the 432 
induction of a protective response remains elusive. The description of the ILC2 cells bridging 433 
the innate and adaptive immune system could potentially shed light to this aspect of 434 
schistosome immunobiology.  435 
 436 
Therefore, apart from the search of new vaccine candidates, new strategies to trigger and 437 
boost the development of effective immune responses should be investigated. ILC2s are of 438 
major importance for the induction of effective type 2 immune responses (Figure 2) and are 439 
in particularly crucial in early immune response and hence are a promising target to boost 440 
responses. Here it is interesting to note that in an experimental mouse model excretory-441 
secretory products of Heligmosomoides polygyrus inhibited the production of TH2 cytokines 442 
by ILC2s through the blockade of IL-33 [123], indirectly indicating the importance for 443 
dampening ILC2 responses for parasite survival. Overcoming such inhibition and efficient 444 
triggering response mediated by ILC2s could be an important step in triggering protective 445 
responses against helminth infections. However, our knowledge of the role of ILC2 biology in 446 
helminth infections is still very limited to allow a predication if modulation of ILC2s can 447 
improve immune response and thereby improve vaccine efficacy.  448 
 449 
For schistosomiasis, protective immune responses can build up over time under constant 450 
exposure [124] and repeated treatment can boost specific immune responses [125]. 451 
Therefore ‘Infection and treatment’ (I&T) strategies are a potential alternative to induce 452 
protective immune responses [126], which so far has proven to be the most efficient 453 
method to induce protection.". The efficacy of this approach has been recently shown for 454 
human malaria infections [127]. Understanding the dynamics of ILC2 involvement in 455 
inducing protective immune responses might better inform targeting of treatment. For 456 
example, we are currently testing the potential for inducing protective immune responses in 457 
schistosomiasis following treatment of the first very infection event. Human immunology 458 
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and mouse experimental studies of helminths and Plasmodium infections suggest that the 459 
number of anti-parasite treatments required to induce protective immune responses can be 460 
reduced by treating people following first infection [128-132]. 461 
 462 
MODULATING ILC2 RESPONSES 463 
Common gamma γc cytokines and their receptors are crucial for homeostasis and activation 464 
of ILC2s and therefore are potential targets to boost ILC2 responses thereby potentially 465 
increase the effectiveness of vaccinations or I&T approaches.  IL-2 therapy has a long history 466 
in antitumor therapy [133] and therapies with low-dose IL-2 are currently tested in 467 
autoimmune disease such as hepatitis C virus-related vasculitis [134] and type 1 diabetes 468 
[135, 136]. Early on, it has been recognised that IL-2 therapy can lead to increased plasma 469 
levels of IL-5 and eosinophila [137, 138] an effect that, at least in mouse models, is caused by 470 
an activation of ILC2s [139]. Side effects of low doses of IL-2 are considered to be relatively 471 
safe, but in the context of autoimmune diseases are used to expand regulatory T cells 472 
(reviewed in [140]), which may contradict attempts to trigger a protective response in 473 
helminth infections. However, with detailed investigations of treatment regimes regarding 474 
the dose and duration of the IL-2 therapy might help to tackle this problem. For instance, 475 
regulatory T cells may expand only after a few weeks of IL-2 therapy, whereas ILC2 activation 476 
may occur quicker in particular if incorporated in I&T approaches or if applied with 477 
vaccinations.      478 
 479 
IL-7, another common gamma γc cytokine is also considered for use in cancer [141-143] and 480 
chronic viral infections [144] highlighting the potential in immunotherapies. This is 481 
particularly important in the carinogenic trematodes, S. haematobium, Opisthorchis viverrini 482 
and Clonorchis sinensis where one of the pathological manifestations of these infections is 483 
cancer in different organs (bladder, bile duct and liver) [145] for which we currently do not 484 
have any therapeutic interventions beyond surgery. Since IL-7 is crucial for the development 485 
and homeostasis of human ILC2s its potential to increase responses mediated by ILC2s in 486 
vaccination and/or I&T protocols should be investigated.  487 
 488 
Apart from the direct use of cytokines in immunotherapies, molecules crucial for the 489 
downstream signalling induced by these cytokine could be targeted. Interestingly, the 490 
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effects by IL-7 in the study on chronic viral infections were partially mediated by repression 491 
of SOCS3 [144]. Hence targeting the JAK/STAT or the MAPK/Erk pathway including SOCS 492 
inhibitors may have the potential to increase ILC2 activation, but also TH2 responses in 493 
general [53, 146].      494 
The main trigger of the ILC2 activity are the alarmins IL-25, IL-33 and TSLP, but their potential 495 
as activators in immunotherapy has not been investigated in detail. However, blocking 496 
alarmins has been considered for treating allergic diseases [147-149], but has not really gone 497 
beyond experimental testing with only initial studies in human [150]. ILC2 targeting alarmins 498 
could be also used in combination with common γc cytokines. Overall, specific modulation of 499 
ILC2 activity to improve vaccine or I&T induced protective immune responses is an exciting 500 
idea. Precise treatment strategies need to be carefully approved to avoid induction of 501 
regulatory T cells or to avoid the induction of allergic immune responses. Before attempting 502 
ILC2 targeting strategies to build up protective immune responses much more work needs to 503 
be done on dissecting mechanisms and signalling pathways in ILC2s.  504 
 505 
CONCLUSIONS 506 
Within a few years of their discovery, ILCs have revolutionised immunology research, added 507 
a new layer of complexity to the immune system as a whole and transformed our 508 
understanding of how immune responses are initiated and maintained. ILCs have been 509 
shown to be important in allergic disorders, autoimmune diseases, viral infections and even 510 
in tumor immunology. Experimental mouse models of helminth infections have led to 511 
increased understanding of the ILC2 biology and provided mechanistic details of the crucial 512 
role of ILC2s in inducing TH2 responses. Human studies testing the hypotheses from these 513 
mouse models lag behind, creating a knowledge gap. However, the limited studies of ILC2s 514 
in the context of natural human infections have already started to yield interesting results 515 
on the nature and function of ILC2s. Given the complexity and diversity of human helminth 516 
infections, much more work needs to be done to obtain a complete figure about the role of 517 
ILC2 and the underlying immunological pathways and mechanisms of their function in 518 
human helminth infections. While the study of the role and function of human ILC is still in 519 
its infancy, rapid incorporation of the knowledge of these cells in our paradigm of the nature 520 
and development of protective immunity is essential for helminth vaccinology and optimal 521 
treatment strategies.      522 
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Figure legends 523 
Figure 1. Identification of human ILC2s by flow cytometry as conducted in our studies. 524 
PBMC were isolated from human peripheral blood and analysed by multi-fluorochrome 525 
based flow cytometry. PBMC were gated on leucocytes (A), single cells (B) and live cells using 526 
a viability dye (C). Live single cells were gated on lineage negative (CD3, CD14, CD16, CD19, 527 
CD20, CD56, CD123, CD11c, αβTCR γδTCR), CD45+ (D), CD127+ (E) and CD161+CRTH2+ cells 528 
(F), which finally leads to the identification of lin-CD45+CD127+CRTH2+CD161+ ILC2s. 529 
 530 
Figure 2. Helminth induced immune responses mediated by ILC2s. Helminth parasites 531 
trigger the secretion of alarmins by endothial or epithelial cells (IL-33, TSLP) [27-29] or by 532 
tuft cells (IL-25) [32-34]. Myeloid cells (dendritic cells (DC) or macrophages) can also release 533 
IL-33 and thereby activate ILC2s [30, 31]. ILC2 activation is maintained and multiplied by IL-4 534 
and IL-9 (acting in an autocrine manner) [36] and require IL-2 and IL-7 for homeostasis and 535 
activation. ILC2s secrets type 2 cytokines upon activation. IL-5 induces eosinophilia [139, 536 
151], IL-4 triggers B cells and induce isotype switiching to IgE. Furthermore, IL-13 can 537 
activate mucus secretion by goblet cells [1, 16, 152], acts on mast cells (potentially in 538 
conjunction with IL-9 [152]) and regulate DC migration [153]. IL-4 and IL-13 can also induce 539 
alternative activated macrophages (AAM) [154]. ILC2s also secrete amphiregulin (Areg) 540 
important for tissue repair [9]. 541 
Furthermore, ILC2s interact with TH2 CD4+ T cells (TH2), which induces TH2 immune response 542 
[43, 155] and IL-2 secreted by T cells could further sustain ILC2 responses and further affect 543 
generation of T cell memory [156], which is altered in chronic helminth infections [84].  544 
Helminth can induce regulatory T cells (Treg), which potentially can dampen the 545 
development of full protective immune response [118]. 546 
 547 
Figure 3. Proportions of ILC2s are diminished in schistosome-infected children and 548 
restored by curative treatment. (A) Proportions of blood CD127+CD294+CD161+ ILC2s were 549 
compared between S. haematobium egg positive (ve+) children and S. haematobium egg 550 
negative (ve-) children (N = 24 per group, age 6-13 years). (B) Proportions of ILC2s of 12 551 
individuals (aged 6-13 years) were compared pre- versus 6 weeks post-treatment. Individuals 552 
were egg positive pre-treatment and had cleared S. haematobium infections after treatment 553 
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with the anti-helminthic drug praziquantel. Figures are reproduced from data published in 554 
[11]. 555 
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